Rodenhuis S
The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Anticancer Drugs. 2001 Feb;12(2):85-8. doi: 10.1097/00001813-200102000-00001.
High-dose chemotherapy was widely viewed as an effective treatment modality in breast cancer until the preliminary results of randomized trials proved disappointing. When it transpired that the author of the two unequivocally positive studies had fabricated data, many decided that high-dose chemotherapy in breast cancer was no longer worth studying. In fact, however, the reported results from randomized studies are consistent with a modest progression-free survival advantage of high-dose chemotherapy over conventional dose. Several more years of data maturation and the results of additional randomized trials must be awaited.
在随机试验的初步结果令人失望之前，大剂量化疗被广泛视为乳腺癌的一种有效治疗方式。当两项明确呈阳性的研究的作者被发现伪造数据时，许多人认定乳腺癌的大剂量化疗不再值得研究。然而，事实上，随机研究报告的结果表明，大剂量化疗在无进展生存期方面比传统剂量化疗有适度优势。必须等待数年的数据成熟以及更多随机试验的结果。
